March 13, 2015
AstraZeneca K.K. (AZ), said on March 12 that it received regulatory approval on March 10 for a pen formulation of its glucagon-like peptide-1 (GLP-1) receptor agonist Bydureon (exenatide) in Japan. According to AZ, the pen formulation is a pre-filled, single-use...read more